A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study.
Nivolumab
Non-small-cell lung cancer
Pembrolizumab
Prognostic factor
Statin
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
06 May 2022
06 May 2022
Historique:
received:
18
03
2021
accepted:
08
03
2022
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
11
5
2022
Statut:
epublish
Résumé
Many studies have recently reported the association of concomitant medications with the response and survival in patients with non-small-cell lung cancer (NSCLC) treated with cancer immunotherapy. However, the clinical impact of statin therapy on the outcome of cancer immunotherapy in patients with NSCLC is poorly understood. In our database, we retrospectively identified and enrolled 390 patients with advanced or recurrent NSCLC who were treated with anti-programmed cell death-1 (PD-1) monotherapy in clinical practice between January 2016 and December 2019 at 3 medical centers in Japan to examine the clinical impact of statin therapy on the survival of patients with NSCLC receiving anti-PD-1 monotherapy. A propensity score-matched analysis was conducted to minimize the bias arising from the patients' backgrounds. The Kaplan-Meier curves of the propensity score-matched cohort showed that the overall survival (OS), but not the progression-free survival (PFS), was significantly longer in patients receiving statin therapy. However, a Cox regression analysis in the propensity score-matched cohort revealed that statin therapy was not an independent favorable prognostic factor, although it tended to be correlated with a favorable outcome. Statin therapy may be a combination tool for cancer immunotherapy in patients with NSCLC. These findings should be validated in further prospective studies with larger sample sizes.
Sections du résumé
BACKGROUND
BACKGROUND
Many studies have recently reported the association of concomitant medications with the response and survival in patients with non-small-cell lung cancer (NSCLC) treated with cancer immunotherapy. However, the clinical impact of statin therapy on the outcome of cancer immunotherapy in patients with NSCLC is poorly understood.
METHODS
METHODS
In our database, we retrospectively identified and enrolled 390 patients with advanced or recurrent NSCLC who were treated with anti-programmed cell death-1 (PD-1) monotherapy in clinical practice between January 2016 and December 2019 at 3 medical centers in Japan to examine the clinical impact of statin therapy on the survival of patients with NSCLC receiving anti-PD-1 monotherapy. A propensity score-matched analysis was conducted to minimize the bias arising from the patients' backgrounds.
RESULTS
RESULTS
The Kaplan-Meier curves of the propensity score-matched cohort showed that the overall survival (OS), but not the progression-free survival (PFS), was significantly longer in patients receiving statin therapy. However, a Cox regression analysis in the propensity score-matched cohort revealed that statin therapy was not an independent favorable prognostic factor, although it tended to be correlated with a favorable outcome.
CONCLUSIONS
CONCLUSIONS
Statin therapy may be a combination tool for cancer immunotherapy in patients with NSCLC. These findings should be validated in further prospective studies with larger sample sizes.
Identifiants
pubmed: 35524214
doi: 10.1186/s12885-022-09385-8
pii: 10.1186/s12885-022-09385-8
pmc: PMC9074359
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
503Informations de copyright
© 2022. The Author(s).
Références
Lung Cancer. 2018 May;119:14-20
pubmed: 29656747
Eur J Cancer. 2021 Feb;144:41-48
pubmed: 33326868
Lung Cancer. 2020 Dec;150:159-163
pubmed: 33171404
Anticancer Res. 2020 Apr;40(4):2209-2217
pubmed: 32234916
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
PLoS One. 2022 Feb 7;17(2):e0263247
pubmed: 35130287
Clin Cancer Res. 2020 Nov 15;26(22):5791-5800
pubmed: 32887721
Nat Rev Cancer. 2016 Nov;16(11):718-731
pubmed: 27562463
N Engl J Med. 2015 Mar 26;372(13):1213-22
pubmed: 25775087
J Thorac Oncol. 2017 Dec;12(12):1798-1805
pubmed: 28939128
Clin Lung Cancer. 2021 Jan;22(1):e57-e62
pubmed: 32900613
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
J Clin Oncol. 2016 Nov 20;34(33):4008-4014
pubmed: 27646948
J Clin Epidemiol. 2001 Apr;54(4):387-98
pubmed: 11297888
Recent Pat Anticancer Drug Discov. 2018;13(2):184-200
pubmed: 29189178
Lung Cancer Manag. 2019 May 07;8(2):LMT11
pubmed: 31645894
Mol Cancer Ther. 2001 Dec;1(2):141-9
pubmed: 12467231
ESMO Open. 2022 Feb;7(1):100348
pubmed: 34942439
N Engl J Med. 2005 May 26;352(21):2184-92
pubmed: 15917383
Lung Cancer. 2018 Dec;126:217-223
pubmed: 29254746
Cancer Immunol Res. 2020 Oct;8(10):1236-1242
pubmed: 32665261
Cell Metab. 2019 Jul 2;30(1):143-156.e5
pubmed: 31031094
Br J Cancer. 2016 Jun 28;115(1):129-35
pubmed: 27280630
Int J Oncol. 2004 May;24(5):1149-57
pubmed: 15067336
Cancer Res. 2005 Aug 15;65(16):7276-82
pubmed: 16105816
Lung Cancer. 2021 Feb;152:27-33
pubmed: 33341085
J Clin Oncol. 2021 Mar 1;39(7):723-733
pubmed: 33449799
Ann Oncol. 2020 Apr;31(4):525-531
pubmed: 32115349
Leukemia. 2002 Apr;16(4):508-19
pubmed: 11960327
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Cell. 2018 Nov 1;175(4):1059-1073.e21
pubmed: 30270039
N Engl J Med. 2012 Nov 8;367(19):1792-802
pubmed: 23134381
Clin Lung Cancer. 2018 May;19(3):e349-e358
pubmed: 29398578
Lancet. 2016 Nov 19;388(10059):2532-2561
pubmed: 27616593
Cell Cycle. 2012 Jul 15;11(14):2583-4
pubmed: 22751434
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Nat Cell Biol. 2014 Apr;16(4):357-66
pubmed: 24658687
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Nature. 1990 Feb 1;343(6257):425-30
pubmed: 1967820
Ann Oncol. 2013 Jun;24(6):1427-34
pubmed: 23508824
Eur J Cancer. 2008 Oct;44(15):2122-32
pubmed: 18707867
Clin Cancer Res. 2012 Jul 1;18(13):3524-31
pubmed: 22529099
Nature. 2020 May;581(7808):310-315
pubmed: 32433607
Int J Cancer. 2021 Jul 15;149(2):473-482
pubmed: 33720422
J Thorac Oncol. 2016 Apr;11(4):487-95
pubmed: 26916631
J Clin Med. 2018 Oct 04;7(10):
pubmed: 30287761
PLoS One. 2018 Dec 20;13(12):e0209486
pubmed: 30571754
Mol Clin Oncol. 2019 Jan;10(1):137-143
pubmed: 30655989
J Clin Oncol. 2004 Jun 15;22(12):2388-94
pubmed: 15197200
JCO Clin Cancer Inform. 2017 Nov;1:1-12
pubmed: 30657380
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Clin Cancer Res. 2000 Mar;6(3):1198-9
pubmed: 10741752
J Epidemiol. 2017 Mar;27(3S):S84-S91
pubmed: 28196737